A recent case report by Lebedev et al1 described a patient presenting with minimal change disease (MCD) within days of his first injection of the BNT162b2 vaccine (Pfizer-BioNTech mRNA-based vaccine against severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]).1 Here, we describe a similar case of a patient with new-onset MCD after this vaccine.